AR059178A1 - Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. - Google Patents

Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer.

Info

Publication number
AR059178A1
AR059178A1 ARP070100305A ARP070100305A AR059178A1 AR 059178 A1 AR059178 A1 AR 059178A1 AR P070100305 A ARP070100305 A AR P070100305A AR P070100305 A ARP070100305 A AR P070100305A AR 059178 A1 AR059178 A1 AR 059178A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluororalkyl
3alkyl
alkylene
fluoralkyl
Prior art date
Application number
ARP070100305A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38309497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059178A1 publication Critical patent/AR059178A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicacion 1: Un compuesto de acuerdo con la formula (1) donde, R1 se selecciona de hidrogeno, halo, alquilo C1-5, fluoralquilo C1-6, alquilen C1-3-Oalquilo C1-3, alquilen C1-3-Ofluoralquilo C1-3, alquilen C1-3NH2, alquilen C1-3NH-alquilo C1-3, alquilen C1-3-N(alquilo C1-3)2, alquilen C1-3-NHfluoralquilo C1-3, alquilen C1-3-N(fluoralquilo C1-3)2, alquilen C1-3-N(alquil C1-3)-fluoralquilo C1-3, hidroxi, alcoxi C1-6, fluoralcoxi C1-6, amino, NHalquilo C1-3, NHfluoralquil C1-3, N(alquil C1- 3)2, N(fluoralquil C1-3)2, N(alquil C1-3)-fluoralquilo C1-3, NH(CO)alquilo C1-3, NH(CO)fluoralquilo C1-3, NH(CO)alcoxi C1-3, NH(CO)fluoralcoxi C1-3, NHSO2alquilo C1-3, NHSO2fluoralquilo C1-3, (CO)alquilo C1-3, (CO)fluoralquilo C1-3, COOH, (CO)alcoxi C1-3, (CO)fluoralcoxi C1-3, (CO)NH2, (CO)NHalquilo C1-3, (CO)NHfluoralquilo C1-3, (CO)N(alquilo C1-3)2, (CO)N(fluoralquilo C1-3)2, (CO)N (alquil C1-3)2-fluoralquilo C1-3, (CO)N(alquileno C4-6), (CO)N(fluoralquileno C4-6), ciano y SO2NH2, R2 se selecciona de hidrogeno, halo, alquilo C1-5, fluoralquilo C1-6, alquilen C1-3-Oalquilo C1-3, alquilen C1-3-Ofluoralquilo C1-3, alquilen C1-3NH2, alquilen C1-3NH-alquilo C1-3, alquilen C1-3-N(alquilo C1-3)2, alquilen C1-3-NHfluoralquilo C1-3, alquilen C1-3-N(fluoralquilo C1-3)2, alquilen C1-3-N(alquil C1-3)-fluoralquilo C1-3, hidroxi, alcoxi C1-6, fluoralcoxi C1-6, amino, NHalquilo C1-3, NHfluoralquil C1-3, N(alquil C1-3)2, N(fluoralquil C1-3)2, N(alquil C1-3)-fluoralquilo C1-3, NH(CO)alquilo C1-3, NH(CO)fluoralquilo C1-3, NH(CO)alcoxi C1-3, NH(CO)fluoralcoxi C1-3, NHSO2alquilo C1-3, NHSO2fluoralquilo C1-3, (CO)alquilo C1-3, (CO)fluoralquilo C1-3, COOH, (CO)alcoxi C1-3, (CO)fluoralcoxi C1-3, (CO)NH2, (CO)NHalquilo C1-3, (CO)NHfluoralquilo C1-3, (CO)N(alquilo C1-3)2, (CO)N(fluoralquilo C1-3)2, (CO)N (alquil C1-3)2-fluoralquilo C1-3, (CO)N(alquileno C4-6), (CO)N(fluoralquileno C4-6) y ciano, o R1 y R2 juntos forman un anillo como se muestra en formula (2); R3 se selecciona de fluor, bromo, yodo, alquilo C1-4, fluoralquilo C1-4, trifluormetilo, alquilen C1-3-Oalquilo C1-3, alquilen C1-3-Ofluoralquilo C1-3, alquilen C1-3-NH2, alquilen C1-3-Nhalquilo C1-3, alquilen C1-3-N(alquilo C1-3)2, alquilen C1-3- NHfluoralquilo C1-3, alquilen C1-3-N(fluoralquilo C1-3)2, alquilen C1-3-N(alquil C1-3)-fluoralquilo C1-3, hidroxi, alcoxi C1-4, fluoralcoxi C1-4, amino, NHalquilo C1-3, NHfluoralquilo C1-3, N(alquilo C1-3)2, N(fluoralquilo C1-3)2, N(alquil C1-3)- fluoralquilo C1-3, NH(alquileno C0-3)G2, N(alquil C0-1 )N(alquilo C0-1)2, N(alquil C0-1)Oalquilo C0-1, NH(CO)alquiloC1-3, NH(CO)fluoralquilo C1-3, NH(CO)G2, (CO)alquilo C1-3, (CO)fluoralquilo C1-3, (CO)alcoxi C1-3, (CO)fluoralcoxi C1-3, (CO)NH2, (CO)NHalquilo C1-3, (CO)NHfluoralquilo C1-3, (CO)N(alquilo C1-3)2, (CO)N(fluoralquilo C1-3)2, (CO)N(alquil C1-3)-fluoralquilo C1-3, (CO)N(alquileno C4-6), (CO)N(fluoralquileno C4-6), (CO)NH2G2, SO2NH2, SO2NHalquilo C1-3, SO2NHfluoralquilo C1-3, SO2N(alquilo C1-3)2, SO2N(fluoralquilo C1-3)2, SO2N(alquil C1-3)-fluoralquilo C1-3, ciano, SO2alquilo C1-6, Salquilo C1-6, Sfluoralquilo C1-6, N(alquileno C4-6) y G1, donde G1 es como se muestra en formula (3); X5 se selecciona de O, NH, Nalquilo C1- 3, y Nfluoralquilo C1-3; G2 es fenilo o un heterociclo aromático de 5 o 6 miembros, sustituido en forma opcional con un sustituyente seleccionado de fluor, bromo, yodo, metilo y metoxi; Q es un heterociclo aromático de 6 miembros que contiene uno o dos átomos de N, donde X1, X2, X3 y X4 se seleccionan en forma independiente de N o C, y donde uno o dos de X1, X2, X3 y X4 es N y el restante es C, y si X4 es C, dicho C se sustituye en forma opcional con fluor o yodo; y uno o más de los átomos de formula (1) es opcionalmente un isotopo detectable; como base libre o una sal, solvato o solvato de una sal aceptable para uso farmacéutico del mismo, con la salvedad de que cuando R1 y R2 son H, R3 metilo, hidroxi, amino, aminofenilo, aminoacetilo o metoxi.
ARP070100305A 2006-01-27 2007-01-24 Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. AR059178A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76265406P 2006-01-27 2006-01-27

Publications (1)

Publication Number Publication Date
AR059178A1 true AR059178A1 (es) 2008-03-12

Family

ID=38309497

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100305A AR059178A1 (es) 2006-01-27 2007-01-24 Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer.

Country Status (20)

Country Link
US (2) US8163928B2 (es)
EP (1) EP1981883A4 (es)
JP (1) JP5289061B2 (es)
KR (1) KR101406248B1 (es)
CN (1) CN101410393B (es)
AR (1) AR059178A1 (es)
AU (1) AU2007207904C1 (es)
BR (1) BRPI0707283A2 (es)
CA (1) CA2640213A1 (es)
EC (1) ECSP088645A (es)
IL (1) IL192876A0 (es)
NO (1) NO20083394L (es)
NZ (1) NZ569667A (es)
RU (1) RU2448106C2 (es)
SA (1) SA07280009B1 (es)
TW (2) TW201018678A (es)
UA (1) UA95267C2 (es)
UY (1) UY30112A1 (es)
WO (1) WO2007086800A1 (es)
ZA (1) ZA200806075B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
JP5603855B2 (ja) 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
ES2554772T3 (es) 2008-05-30 2015-12-23 Merck Sharp & Dohme Corp. Azabenzoxazoles sustituidos novedosos
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
US20110212031A1 (en) * 2008-10-31 2011-09-01 Cyrille Sur Novel substituted azabenzoxazoles
US20120263646A1 (en) * 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP6069661B2 (ja) * 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
WO2012145169A2 (en) 2011-04-21 2012-10-26 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
WO2013040183A1 (en) * 2011-09-16 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
CN102558091B (zh) * 2011-12-22 2014-10-08 合肥工业大学 一种苯并噻唑类衍生物及其用途
CN102659772B (zh) * 2012-05-03 2015-02-11 北京师范大学 一种与Aβ斑块有亲和力的2-芳基苯并杂环化合物及其制备方法和应用
AU2012397435B2 (en) * 2012-12-21 2017-03-30 National Institutes For Quantum And Radiological Science And Technology Novel compound for imaging TAU protein accumulated in the brain
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015051188A1 (en) * 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
US20170216252A1 (en) * 2014-07-11 2017-08-03 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
WO2016010092A1 (ja) * 2014-07-16 2016-01-21 国立研究開発法人科学技術振興機構 ベンゾチアゾール化合物及びこれを含有する医薬
WO2016070107A1 (en) 2014-10-31 2016-05-06 The General Hospital Corporation Potent gamma-secretase modulators
US10292970B2 (en) 2014-12-02 2019-05-21 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
WO2016087371A1 (de) * 2014-12-02 2016-06-09 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
MX2017011579A (es) * 2015-03-12 2018-03-15 Du Pont Pesticidas de tipo azol bicíclicos sustituidos con un heterociclo.
RU2721419C2 (ru) * 2015-08-28 2020-05-19 СиЭйчДиАй ФАУНДЕЙШН, ИНК. Зонды визуализации белка гентингтина
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN111163773A (zh) * 2017-08-02 2020-05-15 斯皮诺吉尼克斯公司 苯并噻唑及相关化合物
SG11202010946YA (en) 2018-05-09 2020-12-30 Aprinoia Therapeutics Inc Heteroaryl compounds and uses thereof
WO2019222454A1 (en) * 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
US20220106330A1 (en) * 2019-01-31 2022-04-07 Spinogenix, Inc. Solid forms of a promoter of spinogenesis
GB201914989D0 (en) * 2019-10-16 2019-11-27 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for TAU Aggregates
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
KR102682408B1 (ko) * 2021-05-12 2024-07-05 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
CN114478431B (zh) * 2022-03-09 2024-07-02 台州学院 一种双取代苯并噻吩类钾离子通道激动剂的制备方法
CN114380731B (zh) * 2022-03-09 2024-07-02 台州学院 一种kcnq钾离子通道激动剂、药物组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU369122A1 (ru) * 1971-01-05 1973-02-08 А. К. Арен, П. П. Заринь, С. К. Германе, Э. С. Лавринович Институт органического синтеза Латвийской ССР Способ получения 4-(бензазолил-2)- 1,2,5,6-тетрагидропиридинов
AU523040B2 (en) * 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
US4556411A (en) * 1984-12-07 1985-12-03 Fmc Corporation Benzothiazole derivatives for plant growth and development modification
JPS6394248A (ja) 1986-10-08 1988-04-25 Canon Inc 電子写真感光体
CA2034309C (en) * 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
EP0735821A4 (en) 1993-12-21 1998-04-01 Lilly Co Eli METHODS FOR TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH AMYLO DOGEN PEPTIDES
US5518713A (en) * 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
EP1345914A1 (en) 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US6696039B2 (en) 2001-04-23 2004-02-24 Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2003045929A1 (fr) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
WO2004087641A1 (ja) 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. ヒドラゾン誘導体
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
MXPA05012120A (es) * 2003-05-13 2006-02-08 Hoffmann La Roche 2-imidazo-benzotiazoles como ligandos de receptores de adenosina.
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1893576A4 (en) 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
WO2007035405A2 (en) 2005-09-16 2007-03-29 University Of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
ES2379987T3 (es) 2005-10-11 2012-05-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compuestos de benzofurano marcados isotópicamente como radiotrazadores para proteínas amiloidógenas
WO2007070173A2 (en) * 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
WO2008118122A2 (en) * 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101641354A (zh) 2007-01-22 2010-02-03 阿斯利康(瑞典)有限公司 杂芳基取代的新咪唑并[1，2-a]吡啶衍生物

Also Published As

Publication number Publication date
ZA200806075B (en) 2012-12-27
TW200736252A (en) 2007-10-01
WO2007086800A1 (en) 2007-08-02
EP1981883A1 (en) 2008-10-22
EP1981883A4 (en) 2010-10-06
CN101410393B (zh) 2012-01-25
NO20083394L (no) 2008-10-02
CA2640213A1 (en) 2007-08-02
JP2009528271A (ja) 2009-08-06
US20090028787A1 (en) 2009-01-29
AU2007207904A1 (en) 2007-08-02
US8957215B2 (en) 2015-02-17
UY30112A1 (es) 2007-08-31
ECSP088645A (es) 2008-08-29
RU2448106C2 (ru) 2012-04-20
AU2007207904C1 (en) 2011-10-13
KR101406248B1 (ko) 2014-06-19
BRPI0707283A2 (pt) 2011-04-26
JP5289061B2 (ja) 2013-09-11
TW201018678A (en) 2010-05-16
US8163928B2 (en) 2012-04-24
RU2008130965A (ru) 2010-03-10
CN101410393A (zh) 2009-04-15
AU2007207904B2 (en) 2011-03-10
KR20080090542A (ko) 2008-10-08
IL192876A0 (en) 2009-02-11
NZ569667A (en) 2011-09-30
UA95267C2 (en) 2011-07-25
SA07280009B1 (ar) 2011-07-20
US20120207679A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
AR059178A1 (es) Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer.
ES2271615T3 (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados y su uso como antibacterianos.
AR061515A1 (es) Benzoxazoles sustituidos con heteroarilo. composiciones farmaceuticas.
UY26727A1 (es) Derivados de tropano útiles en terapia
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
AR054551A1 (es) Metodos para la neuroproteccion
AR071385A1 (es) Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia.
CO6270228A2 (es) Derivados de quinazilinona 6-, 7-, u 8 -sustituidos y composiciones que los comprenden y metodos para usar los mismos
ES2623982T3 (es) Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
CR8859A (es) Derivados de piridina
AR064521A1 (es) Activador de glucoquinasa
AR081387A1 (es) Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos.
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
AR067058A1 (es) Oxazolidinonas sustituidas y su uso para preparar medicamentos
AR054341A1 (es) Combinaciones sinergicas de compuestos activos fungicidas
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ECSP045078A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplásicos
AR062405A1 (es) Derivados de isoindol
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
DOP2010000063A (es) Mejoras en compuestos organicos o relacionadas con los mismos
AR046311A1 (es) Derivados de 1,2,4 tiadiazoles. composiciones farmaceuticas.
AR044453A1 (es) Derivados de metoxi-pirazin-tienil sulfonamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure